By Nicoletta Lanese
"...Primary care doctors have a big opportunity to better spot depressive symptoms in at-risk patients and help improve their lives through treatment,” says Matthew Hirschtritt, MD, MPH, a forensic psychiatry fellow at UC San Francisco and first author of a new study. Photo by Steve Babuljak
Hazardous alcohol use and depression often go hand-in-hand. Yet when a patient is screened by their doctor for hazardous alcohol use, rarely are they also screened for depression.
A new study has identified at-risk populations for whom depression screening combined with hazardous alcohol use screening could detect depressive symptoms that might otherwise go untreated. These populations include non-white and more medically ill patients, and men in general, for whom screening rates are particularly low.
“Our study provides evidence that, with a simple questionnaire, primary care doctors have a big opportunity to better spot depressive symptoms in at-risk patients and help improve their lives through treatment,” said Matthew Hirschtritt, MD, MPH, a forensic psychiatry fellow at UC San Francisco and first author of the new study.
Hirschtritt conducted the study in collaboration with the paper’s senior author, Stacy Sterling, DrPH, of the Division of Research of Kaiser Permanente Northern California (KPNC). Their findings were published September 10, 2018, in the Journal of the American Board of Family Medicine.
Depression is common, screening is not
The negative health effects of excessive alcohol consumption are now well recognized, and screening for hazardous drinking is becoming more standard in primary care, but it wasn’t always. KPNC boosted the practice within its own healthcare system through the “Alcohol as a Vital Sign” initiative, which provided data for the current study. Their slogan is “We ask everyone,” meaning every adult primary care patient can expect to be screened about alcohol use.
Screening for depression is not as common, however, despite its common comorbidity with hazardous drinking. The U.S. Preventive Services Task Force recommends that primary care practitioners screen for depressive symptoms using an instrument known as the Patient Health Questionnaire 9. The questionnaire is effective, when it’s used. But clinicians must prioritize which recommendations to act upon in a given appointment, or a simple check-up would be hours long. As a result, depression screening is part of only about 1.4 percent of adult ambulatory care visits nationwide.
But given the prevalence of depressive symptoms in the U.S., the authors argue that forgoing screening means missing an opportunity to help patients.
“Depressive symptoms are extremely common, but we know many people don’t make it to specialty psychiatric treatment,” said Sterling. “Many people do already have a strong relationship with their primary care provider, so it may actually be the perfect environment for behavioral health intervention.”
Surprising discrepancies in screening
The study utilized data from more than 2,800,000 KPNC primary care patients who had been screened for hazardous alcohol use. Per national guidelines, patients were asked how many days they typically drank per week, and how many drinks they consumed on those days. Hazardous use was defined as more than 14 drinks a week for men 65 and younger, and more than 7 drinks a week for women and men 66 and over.
In addition to participants’ drinking habits, the researchers analyzed electronic health records to determine whether they were screened for depression with the recommended health questionnaire. They found that among patients screened for hazardous alcohol use, 2.4 percent were also screened for depression within the next 30 days, which is consistent with estimates from national surveys. The depression screening rate was lower for non-whites, men, and those who were more medically ill.
“The finding that I found most concerning is that individuals who self-identified as White were more likely to receive screening than were historically marginalized ethnic groups,” said Hirschtritt. Though the study potentially underestimates absolute rates of depression screening, because doctors could screen patients for depression using methods other than the recommended questionnaire, the observed discrepancy in screening rates was still a red flag, Hirschtritt said.
Although non-white patients, including Black, Hispanic, Asian, and those categorized as “other/unknown,” were less likely to be screened for depression than White patients, these patients were more likely to report clinically significant depressive symptoms. Similarly, although less medically sick patients were less likely to be screened than healthier patients, they were more likely to report clinically significant depressive symptoms.
Discrepancies in screening and rates of depressive symptoms by ethnicity and medical illness are concerning, the authors said, given that some groups are more vulnerable to depression than others.
“It’s unclear why non-white individuals weren’t screened at a higher rate,” Hirschtritt said. “These patients may face multiple stressors that put them at a higher risk for depression, in addition to hazardous alcohol use.”
Boosting the numbers
When surveyed, approximately 8.1 percent of U.S. adults have exhibited significant depressive symptoms in the past two weeks, while 21.6 percent have had some depressive symptoms at some point. Primary care settings are an “untapped resource” to treat this prevalent condition, Hirschtritt said.
He said that innovative healthcare models, such as integrative and collaborative care, are being adopted and serve to empower primary care practitioners to address mental health in the clinic. Physicians can also seek consults from psychiatrists, with mental health professionals as their in-house liaisons.
The Alcohol as a Vital Sign initiative equipped practitioners with clear protocols for screening, training for brief intervention and handy tools built into electronic health records -- and both Hirschtritt and Sterling suggested these strategies could applied to depression screening, as well.
“The Alcohol as a Vital Sign initiative has resulted in extremely high screening and brief intervention rates,” said Sterling. “It could make a difference if we established a similar protocol for depression.”
First author Matthew Hirschtritt, MD, MPH, is a forensic psychiatry fellow and researcher in the UCSF Department of Psychiatry and a member of the UCSF Weill Institute for Neurosciences. Stacy Sterling, DrPH, MPH, MSW, is with the Drug and Alcohol Research Team (DART) and the Behavioral Health Research Initiative at the KPNC Division of Research; she is senior author of the study. Additional authors are Andrea Kline-Simon, MS, of the KPNC Division of Research; and Kurt Kroenke, MD, of the Indiana University School of Medicine and the Regenstrief Institute, Inc.
The research was supported by a grant (R01-AA025902–01) to Sterling from the National Institute on Alcohol Abuse and Alcoholism and a training grant (R25-MH060482–17) to Hirschtritt from the National Institute of Mental Health.
Read the paper
- Journal of the American Board of Family Medicine: Depression screening rates and symptom severity by alcohol use among primary care adult patients
About UCSF Psychiatry
The UCSF Department of Psychiatry, UCSF Langley Porter Psychiatric Hospital, and the Langley Porter Psychiatric Institute are among the nation's foremost resources in the fields of child, adolescent, adult, and geriatric mental health. Together they constitute one of the largest departments in the UCSF School of Medicine and the UCSF Weill Institute for Neurosciences, with a mission focused on research (basic, translational, clinical), teaching, patient care, and public service.
UCSF Psychiatry conducts its clinical, educational and research efforts at a variety of locations in Northern California, including UCSF campuses at Parnassus Heights, Mission Bay and Laurel Heights, UCSF Medical Center, UCSF Benioff Children's Hospitals, Zuckerberg San Francisco General Hospital and Trauma Center, the San Francisco VA Health Care System, and UCSF Fresno.
About the UCSF Weill Institute for Neurosciences
The UCSF Weill Institute for Neurosciences, established by the extraordinary generosity of Joan and Sanford I. "Sandy" Weill, brings together world-class researchers with top-ranked physicians to solve some of the most complex challenges in the human brain.
The UCSF Weill Institute leverages UCSF’s unrivaled bench-to-bedside excellence in the neurosciences. It unites three UCSF departments—Neurology, Psychiatry, and Neurological Surgery—that are highly esteemed for both patient care and research, as well as the Neuroscience Graduate Program, a cross-disciplinary alliance of nearly 100 UCSF faculty members from 15 basic-science departments, as well as the UCSF Institute for Neurodegenerative Diseases, a multidisciplinary research center focused on finding effective treatments for Alzheimer’s disease, frontotemporal dementia, Parkinson’s disease, and other neurodegenerative disorders.
About UCSF
UC San Francisco (UCSF) is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with nationally renowned programs in basic, biomedical, translational and population sciences; and a preeminent biomedical research enterprise.
It also includes UCSF Health, which comprises three top-ranked hospitals – UCSF Medical Center and UCSF Benioff Children’s Hospitals in San Francisco and Oakland – as well as Langley Porter Psychiatric Hospital, UCSF Benioff Children’s Physicians, and the UCSF Faculty Practice. UCSF Health has affiliations with hospitals and health organizations throughout the Bay Area. UCSF faculty also provide all physician care at the public Zuckerberg San Francisco General Hospital and Trauma Center, and the San Francisco VA Medical Center. The UCSF Fresno Medical Education Program is a major branch of the University of California, San Francisco’s School of Medicine.
